Evaluation of intangible assets in the cuban biopharmaceutical industry: a neuroprotection project as a case study
Keywords:
negotiation, project, intangible assets, biopharmaceutical, cerebral ischemiaAbstract
The Center for Genetic Engineering and Biotechnology has developed a project, based on the co-administration of Epidermal Growth Factor (EGF) and Growth Hormone Releasing Peptide 6 (GHRP6) for its application in the indication of ischemic stroke. The article aims to develop a prospective business proposal for the introduction of the project in the international market. The four stages deployed for project negotiation are presented: characterization of the product and its application, definition of the target market, determination of the value of the project and proposal of the business model. The negotiation proposal can be generalized to many other innovative Research and Development (R&D) projects in the Cuban Biopharmaceutical industry.
Downloads
References
Thrift AG, Thayabaranathan T, Howar Vj, Rthwell PM, Feigin VL, et al. Global stroke statistics. Int J Stroke 2017; 12:13-32 [Consultado 5 noviembre 2019] Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27794138
Gil de CR, Gil-Nunez AC. Risk factors for ischemic stroke. I. Conventional risk factors. Rev Neurol 2000 Aug 16; 31(4):314-23 [Consultado 10 noviembre 2019] Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/11008287
Kim AS, Johnston SC. Temporal and geographic trends in the global stroke epidemic. Stroke 2013 Jun; 44(6 Suppl 1): S123-S125. [Consultado 8 diciembre 2019] Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23709707
Béjot Y, Delpont B, Giroud M. Rising stroke incidence in Young adults: More epidemiological evidence, more questions to be anwered. Journal of the American Heart Association 2016,5: e003661. https://doi.org/10.1161/JAHA.116.003661 [Consultado 8 diciembre 2019] Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889213/
MINSAP Anuario estadístico de salud 2017. Dirección de registros médicos y estadísticos de salud. 2018. [Consultado 5 julio 2019] Disponible en: http://www.sld.cu/anuncio/2018/04/06/publicado-el-anuario-estadistico-de-salud-2017
Martínez NS, Machado JM, Pérez H, Coro RM, Berlanga JA, Salgueiro SR, Illera GG, Alba JS, Del Barco DG. Global brain ischemia in Mongolian gerbils: assessing the level of anastomosis in the cerebral circle of Willis. Acta Neurobiol Exp (Wars). 2012;72(4):377-84. [Consultado 5 julio 2019] Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23377268
Del Barco DG, Montero E, Coro RM, Brown E, Suareza J, Lopez L, Subirós N, Berlanga J. Coadministration of epidermal growth factor and growth hormone releasing peptide-6 improves clinical recovery in experimental autoimmune encephalitis. Restor Neurol Neurosci. 2011;29(4):243-52. doi: 10.3233/RNN-2011-0595. [Consultado 5 octubre 2019] Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/21697595
Subirós NI, Pérez H, Aldana L, Gibson CL, Borgnakke WS, García D. Neuroprotective effect of epidermal growth factor plus growth hormone-releasing peptide-6 resembles hypothermia in experimental stroke. Neurological Research. 2016 Nov;38(11):950-958. Epub 2016 Sep 26. DOI:10.1080/01616412.2016.1235249 [Consultado 5 octubre 2019] Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27665924
Del Barco G, Martínez NS, Coro RM, Machado JM, Alba JS, Salgueiro SR, Acosta JB. Epidermal growth factor and growth hormone-releasing peptide-6: combined therapeutic approach in experimental stroke. Restor Neurol Neurosci. 2013;31(2):213-23. doi: 10.3233/RNN-120262. [Consultado 1 noviembre 2019] Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23314006
Chesbrough H.W. The Era of Open Innovation. MIT Sloan Management Review. Cambridge. Magazine: Spring. 2003;44(3):35–41. [consultado 1 noviembre de 2019]. Disponible en: http://sloanreview.mit.edu/article/the-era-of-open-innovation/
Rasmussen B. Trends in Biopharmaceutical Alliances for the Key Business Models. Working Paper No. 37. Pharmaceutical Industry Project. Working Paper Series. Centre for Strategic Economic Studies Victoria University of Technology. December 2007 [Consultado 5 noviembre 2019] Disponible en: https://www.researchgate.net/publication/228404329_Trends_in_Biopharmaceutical _Alliances_the_Key_Business_Models
Delgado M. Enfoque para la gestión de la I+D+i en la Industria Biofarmacéutica cubana. Revista Cubana de Información en Ciencias de la Salud. [Internet]. 2017; 28(3). [Consultado 5 noviembre 2019] Disponible en: http://scielo.sld.cu/pdf/ics/v28n3/rci02317.pdf
Insoo D, Kim E. Factors Affecting the Outbound Open Innovation Strategies in Pharmaceutical Industry: Focus on Out-Licensing Deal. J. Open Innov. Technol. Mark. Complex. 2019, 5, 73; doi:10.3390/joitmc5040073. [Consultado 26 noviembre 2019] Disponible en: http://www.mdpi.com/journal/joitmc
Radio Habana Cuba. [Internet]. La Habana: Radiohc;1 julio 2019 [Consultado 5 noviembre 2019] Celebra Centro cubano de Ingeniería Genética y Biotecnología 33 años de fundado. [aprox.1pantalla]. Disponible en: http://www.radiohc.cu/noticias/ciencias/194813-celebra-centro-cubano-de-ingenieria-genetica-y-biotecnologia-33-anos-de-fundado
Elias CU. Commercialization Strategies of Research Providers and their Realization in the Negotiation Process – An Exploratory Analysis. [Master’s Thesis]. Supervisor: Kloyer M. Aarhus: School of Business and Social Science Aarhus University, Innovation Management Department of Marketing and Statistics; May 2011:72 pages. [Consultado 5 octubre 2019] Disponible en: https://pdfs.semanticscholar.org/645e/4694c6eee9c37f9d69295c2f123518bd957a. pdf
Ocean Tomo 300® Patent Index. Intangible Asset Market Value Study. 2019. [Consultado 10 diciembre 2019] Disponible en: https://www.oceantomo.com/intangible-asset-market-value-study/
Conover TL, Liu X, Poli PM. The Value Relevance of Key Accounting Information for Biotech Firms at the IPO: A Test of Assets, Cumulative R&D Expenses, and Cumulative Losses. p. 9. [Consultado 3 noviembre 2019] Disponible en: http://www.jgbm.org/page/27%20Patricia%20M. %20Poli%20.pdf
Lemmetyinen J. Commercialization of Biopharmaceuticals. [Master’s Thesis]. Supervisor: Gabrielsson M. Helsinki: Lappeenranta University of Technology Department, Department of Business Administration; 2001:100 pages. [Consultado 5 diciembre 2019] Disponible en: https://lutpub.lut.fi/bitstream/handle/10024/34360/nbnfi-fe20011145.PDF?sequence=1
Zaharoff HG. Setting Values and Royalty Rates for Medical and Life Sciences Businesses. June 18; 2012. A version of this article appeared in The Journal of Biolaw and Business, Vol. 7, No. 4, 2004 [Consultado 10 noviembre 2019] Disponible en: https://www.morse.law/news/setting-values-and-royalty-rates
Espinosa MM, Lage A, Delgado M. Evolución de la gestión organizacional en un centro cubano de la biotecnología. Ingeniería Industrial. septiembre-diciembre 2017; XXXVIII(3): 311-322. [Consultado 10 noviembre 2019] Disponible en: http://rii.cujae.edu.cu/index.php/revistaind/article/ view/794/810
Delgado M, Lage A, Ojito E, Espinosa M, Arias MA. Visión de la innovación en un centro cubano de la biotecnología aplicada a la salud. Revista Cubana de Salud Pública. 2020;46(1):e1941. [Consultado 15 enero 2020] Disponible en: http://www.revsaludpublica.sld.cu/index.php/spu/ article/view/1941
Molloy P. Value creation and investor performance of the Australian drug development biotech sector. [Doctor’s Thesis]. Supervisors: Johnson L and Gilding M. Melbourne: Faculty of Business and Law Swinburne University of Technology; 2019 [Consultado 20 diciembre 2019] Disponible en: https://researchbank.swinburne.edu.au/file/0a7ee27f-bef3-4a7c-b32d-87e2c3df372f/1/peter_ molloy_ thesis.pdf
Blanco E. Role of Business Models in Funding the Biotech Industry: Global Trends and Challenges for Cuban Biotechnology. MEDICC Review, January 2020, Vol 22, No 1. 2019 [Consultado 10 diciembre 2019] Disponible en: https://mediccreview.org/wp-content/uploads/2020/02/MR-January2020-Blanco-Role-of-business.pdf
Shuaib A, Hussain MS. The past and future of neuroprotection in cerebral ischaemic stroke. EurNeurol 2008;59(1-2):4-14. [Consultado 1 diciembre 2019] Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/17917451
MINSAP. Anuario Estadístico de Salud. Dirección Nacional de registros médicos y estadísticas de salud. 2009; p. 243 [Consultado 1 diciembre 2019] Disponible en: http://files.sld.cu/bvscuba/files/2013/05/anuario-2009e3.pdf
Green AR. Pharmacological approaches to acute ischaemic stroke: reperfusion certainly,neuroprotection possibly. Br J Pharmacol 2008 Mar;153 Suppl 1:S325-S338. [Consultado 5 noviembre 2019] Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/18059324
Siren AL, Ehrenreich H. Erythropoietin—a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci 2001 Aug;251(4): 179-84. [Consultado 5 noviembre 2019] Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/11697582
Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 2008 Sep;55 (3): 363-89. [Consultado 10 noviembre 2019] Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2631228/
Ginsberg MD. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke 2009 Mar;40(3 Suppl):S111-S114. [Consultado 10 noviembre 2019] Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697575/
Kolchinsky Peter. The Entrepreneur´s Guide to a Biotech Startup, 4th edn. Report Evelexa; 2004 [Consultado 20 noviembre 2019] Disponible en: https://www.ctsi.ucla.edu/researcher-resources/files/view/docs/EGBS4_Kolchinsky.pdf
Spasic O. Introduction to the Basic IP Valuation issues. National workshop on innovation promotion and technology transfer. WIPO, Ankara, December 19 and Istanbul 21; 2012. [Consultado 20 noviembre 2019] Disponible en: https://slideplayer.com/slide/5795234/
Stewart J. Biotechnology valuations for the 21st Century. Policy Brief Milken Institute, California, April 2002;Number 27. [Consultado 20 noviembre 2019] Disponible en: https://assets1c.milkeninstitute.org/assets/Publication/ResearchReport/PDF/biotechPB.pdf
DiMasi JA1, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003 Mar;22(2):151-85. [Consultado 10 noviembre 2019] DOI: 10.1016/S0167-6296(02)00126-1 Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/12606142
Delgado M. La calidad y la innovación tecnología en la biotecnología aplicada a la salud. Dirección y organización: Revista de dirección, organización y administración de empresas, Madrid, 1998; Número 19: 125-132. [Consultado 15 noviembre 2019] Disponible en: https://www.revistadyo.com/index.php/dyo/article/view/332/332
Delgado M. Tendencias en los sistemas de gestión de calidad en la I+D Biofarmacéutica. Biotecnología Aplicada. 1998; 15: 111-116. [Consultado 15 noviembre 2019] Disponible en: http://elfosscientiae.cigb.edu.cu/PDFs/Biotecnol%20Apl/1998/15/2/111-116.pdf
Sertkaya A, Wong HH, Jessup A, Beleche T. Key cost drivers of pharmaceutical clinical trials in the United States. Clinical Trials Journal. 2016 Apr;13(2):117-26. doi: 10.1177/1740774515625964. Epub 2016 Feb 8. [Consultado 10 noviembre 2019] Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/26908540
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Miladys Limonta Fernández, Miriam Beltrán Martínez, Rolando Páez Meireles, Mercedes Delgado Fernández
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
-
NonCommercial — You may not use the material for commercial purposes.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
scholar.google.com.cu
